Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE: Songling Xuemaikang Capsules in Hypertension and Insomnia
NCT07709442Not yet recruiting
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Randomised, double-blind trial of songling xuemaikang in hypertension (HTN) and Insomnia (2 arms). Primary endpoint: Change from baseline in 24-hour mean systolic blood pressure at 12 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
songling xuemaikang
03
Conditions
hypertension (HTN)Insomnia
Beyond the preview
Go deeper on NCT07709442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07709442.